Kim M. Pabst

788 total citations
33 papers, 351 citations indexed

About

Kim M. Pabst is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Kim M. Pabst has authored 33 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 20 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Surgery. Recurrent topics in Kim M. Pabst's work include Peptidase Inhibition and Analysis (19 papers), Radiopharmaceutical Chemistry and Applications (17 papers) and Medical Imaging Techniques and Applications (9 papers). Kim M. Pabst is often cited by papers focused on Peptidase Inhibition and Analysis (19 papers), Radiopharmaceutical Chemistry and Applications (17 papers) and Medical Imaging Techniques and Applications (9 papers). Kim M. Pabst collaborates with scholars based in Germany, United States and Switzerland. Kim M. Pabst's co-authors include Wolfgang P. Fendler, Ken Herrmann, Rainer Hamacher, Jens T. Siveke, Lale Umutlu, Lukas Kessler, Christoph Rischpler, Katharina Lueckerath, Sebastian Bauer and Manuel Weber and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Kim M. Pabst

29 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kim M. Pabst Germany	10	200	119	104	96	72	33	351
Tülay Kuş Türkiye	12	260 1.3×	66 0.6×	133 1.3×	77 0.8×	73 1.0×	47	416
Márcio Debiasi Brazil	9	115 0.6×	45 0.4×	39 0.4×	60 0.6×	142 2.0×	24	294
Tokiko Ito Japan	12	142 0.7×	36 0.3×	124 1.2×	75 0.8×	45 0.6×	37	431
Kazumi Noguchi Japan	12	110 0.6×	98 0.8×	71 0.7×	37 0.4×	235 3.3×	58	485
Aydın Aytekin Türkiye	8	197 1.0×	48 0.4×	69 0.7×	102 1.1×	45 0.6×	25	259
Yunus Güzel Türkiye	10	274 1.4×	94 0.8×	170 1.6×	171 1.8×	42 0.6×	40	376
Toshihide Monden Japan	9	82 0.4×	214 1.8×	62 0.6×	26 0.3×	89 1.2×	17	362
Charlotte Andersson Sweden	5	118 0.6×	167 1.4×	49 0.5×	18 0.2×	164 2.3×	7	302
Ruofei Liang China	12	78 0.4×	44 0.4×	33 0.3×	94 1.0×	52 0.7×	23	357
Lucianna Russo Italy	8	137 0.7×	92 0.8×	25 0.2×	70 0.7×	286 4.0×	15	367

Countries citing papers authored by Kim M. Pabst

Since Specialization

Citations

This map shows the geographic impact of Kim M. Pabst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim M. Pabst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim M. Pabst more than expected).

Fields of papers citing papers by Kim M. Pabst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim M. Pabst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim M. Pabst. The network helps show where Kim M. Pabst may publish in the future.

Co-authorship network of co-authors of Kim M. Pabst

This figure shows the co-authorship network connecting the top 25 collaborators of Kim M. Pabst. A scholar is included among the top collaborators of Kim M. Pabst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim M. Pabst. Kim M. Pabst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pabst, Kim M., Viktor Grünwald, Kuangyu Shi, et al.. (2025). Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3199–3210. 1 indexed citations

Duiverman, Marieke L., Martijn D. de Kruif, Daniela E. Oprea‐Lager, et al.. (2025). [68Ga]FAPI PET/CT reveals increased pulmonary fibroblast activation protein expression in long COVID patients after ICU discharge. European Journal of Nuclear Medicine and Molecular Imaging. 53(1). 565–573. 1 indexed citations

Pabst, Kim M., et al.. (2025). The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update. Seminars in Nuclear Medicine. 55(5). 701–709. 1 indexed citations

Grünwald, Viktor, et al.. (2025). New targets of PET imaging for renal cancer. Seminars in Nuclear Medicine. 56(2). 144–151.

Heilig, Christoph E., Eva Wardelmann, Kim M. Pabst, et al.. (2025). ⁹⁰Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors. Journal of Nuclear Medicine. 66(9). 1378–1384. 2 indexed citations

Watanabe, Masao, Wolfgang P. Fendler, Hong Grafe, et al.. (2024). Prognostic Implications of⁶⁸Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors. Journal of Nuclear Medicine. 65(7). 1027–1034. 9 indexed citations

Rahbar, Kambiz, Michal Sarfaty, Raya Leibowitz‐Amit, et al.. (2024). 1629P Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra). Annals of Oncology. 35. S983–S984. 1 indexed citations

Pabst, Kim M., Riccardo Mei, Katharina Lückerath, et al.. (2024). Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 52(1). 342–353. 8 indexed citations

Lückerath, Katharina, Jens T. Siveke, Benedikt M. Schaarschmidt, et al.. (2023). Novel Ga-68-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls. Nuklearmedizin - NuclearMedicine. 62(2). 129–129. 2 indexed citations

10.

Fendler, Wolfgang P., Kim M. Pabst, Rainer Hamacher, et al.. (2023). ⁶⁸Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.. Journal of Clinical Oncology. 41(16_suppl). 3064–3064. 1 indexed citations

11.

Pabst, Kim M., Marija Trajkovic‐Arsic, Phyllis F. Cheung, et al.. (2023). Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. Journal of Nuclear Medicine. 64(7). 1049–1055. 32 indexed citations

12.

Giovanella, Luca, Lisa Milan, Wolfgang Roll, et al.. (2023). Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2767–2774. 7 indexed citations

13.

Ludwig, Johannes, Catherine Leyh, Kim M. Pabst, et al.. (2023). Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab. Cancers. 15(17). 4274–4274. 3 indexed citations

14.

Fendler, Wolfgang P., Kim M. Pabst, Lukas Kessler, et al.. (2022). Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clinical Cancer Research. 28(19). 4346–4353. 91 indexed citations

15.

Pabst, Kim M., Ken Herrmann, Christoph Rischpler, et al.. (2022). Thyroiditis: A pitfall in Ga-68-FAPI-PET/CT?. Nuklearmedizin - NuclearMedicine. 61(2). 195–195.

16.

Rahbar, Kambiz, Markus Essler, Vikas Prasad, et al.. (2022). 1392P Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes. Annals of Oncology. 33. S1180–S1180. 2 indexed citations

17.

Rahbar, Kambiz, Markus Essler, Kim M. Pabst, et al.. (2022). Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RALU Study. Journal of Nuclear Medicine. 64(4). 574–578. 21 indexed citations

18.

Rahbar, Kambiz, Markus Essler, Matthias Eiber, et al.. (2022). Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium-223 (²²³Ra): Interim analysis of the RALU study.. Journal of Clinical Oncology. 40(16_suppl). 5040–5040. 2 indexed citations

19.

Pabst, Kim M., Robert Seifert, Nader Hirmas, et al.. (2022). Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer. Endocrine Connections. 12(2). 1 indexed citations

20.

Christmas, Colleen, Karen G. O’Connor, S. Mitchell Harman, et al.. (2002). Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men. The Journals of Gerontology Series A. 57(1). M12–M18. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact